GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Current Accrued Expense

CG Oncology (CG Oncology) Current Accrued Expense : $3.06 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Current Accrued Expense?

CG Oncology's Current Accrued Expense for the quarter that ended in Mar. 2024 was $3.06 Mil.

CG Oncology's quarterly Current Accrued Expense increased from Sep. 2023 ($5.17 Mil) to Dec. 2023 ($6.51 Mil) but then declined from Dec. 2023 ($6.51 Mil) to Mar. 2024 ($3.06 Mil).

CG Oncology's annual Current Accrued Expense increased from Dec. 2021 ($0.82 Mil) to Dec. 2022 ($3.28 Mil) and increased from Dec. 2022 ($3.28 Mil) to Dec. 2023 ($6.51 Mil).

CG Oncology Current Accrued Expense Historical Data

The historical data trend for CG Oncology's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Current Accrued Expense Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Current Accrued Expense
0.82 3.28 6.51

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Current Accrued Expense Get a 7-Day Free Trial 3.28 - 5.17 6.51 3.06

CG Oncology Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

CG Oncology Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of CG Oncology's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Current Accrued Expense
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024